Galeterone

Galeterone

Clinical data
Routes of administration	Oral
Identifiers
IUPAC name 17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-ol
CAS Number	851983-85-2
PubChem CID	11188409
ChemSpider	9363493
UNII	WA33E149SW
KEGG	D10125 Y
ECHA InfoCard	100.233.599
Chemical and physical data
Formula	C26H32N2O
Molar mass	388.25
3D model (Jmol)	Interactive image
SMILES C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O
InChI InChI=1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1 Key:PAFKTGFSEFKSQG-PAASFTFBSA-N

Galeterone (TOK-001 or VN/124-1) is a novel steroidal antiandrogen that was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and a CYP17A1 inhibitor, the latter of which prevents the biosynthesis of androgens. As a CYP17A1 inhibitor, galeterone shows selectivity for 17,20-lyase over 17α-hydroxylase.

Galeterone was being compared to enzalutamide in a phase III clinical trial (ARMOR3-SV) for AR-V7-expressing metastatic castration-resistant prostate cancer. Tokai announced the discontinuation of ARMOR3-SV on July 26, 2016, after a data monitoring committee determined that the trial was unlikely to meet its endpoint. On August 22, 2016, the company announced the discontinuation of their phase II expansion (ARMOR2) as well.

In the week following cancellation of the ARMOR3-SV clinical trial, Tokai announced a reduction of its workforce by around 60% to a total of 10 "full-time equivalent employees." On December 22, 2016, a definitive share purchase agreement was announced, under which shareholders of Otic Pharma Ltd. would become the majority owners of Tokai Pharmaceuticals Inc., resulting in a NASDAQ-listed company (OticPharma, Inc.) focused on the development and commercialization of products for ear, nose, and throat disorders.